laryngeal squamous cell carcinoma
Conditions
Interventions
Observation group:none
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent voluntarily; 2. Male or female, aged 40-75 years (not including 75); 3. Patients with laryngeal squamous cell carcinoma diagnosed for the first time through tissue biopsy or surgical specimen; 4. The subject has not received any of the following anti-tumor treatments before the collection of tissue samples: tumor surgery for any purpose, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti angiogenesis), immunotherapy, cancer vaccine, hormone therapy.
Exclusion criteria
Exclusion criteria: 1. Female subjects who were pregnant or lactating at the time of sample collection; 2. Have received organ transplantation or non autologous bone marrow or stem cell transplantation in the past; 3. Within 30 days before the collection of samples, they have received drugs with anti-tumor effects due to other diseases, such as methotrexate, cyclophosphamide, mercaptopurine, nitrogen mustard phenylbutyrate, etc., used for immune rheumatic drugs, and tamoxifen, etc., used for breast diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tissue DNA methylatio; | — |
Countries
China
Contacts
Public ContactJiping Li
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Outcome results
None listed